P.V. Sychev1, Yu.D. Udalov1, E.V. Mayakova1, O.E. Klementieva2
1Federal Scientific Clinical Center for Medical Radiology and Oncology of FMBA, Dimitrovgrad
2N.N. Blokhin National Medical Research Center of Oncology, Moscow
Sychev Petr V. ― Head of the Nuclear Medicine Center, radiologist of the Federal Scientific Clinical Center for Medical Radiology and Oncology of FMBA
5v Kurchatov Str., Dimitrovgrad, 433507, Russian Federation, tel. +7-910-219-12-33, e-mail: sychevpetr@gmail.com, SPIN-code: 1612-7320, ORCID ID: 0000-0003-3965-4661
Abstract. Every year the number of patients diagnosed with malignant neoplasms is growing and, at the same time, the number of patients in need of palliative treatment is increasing. Metastatic bone lesions are one of the most common manifestations of cancer progression. The problem of treating bone metastases in patients with cancer remains relevant and attracts the attention of oncologists of various specialties.
Currently, a foreign drug is registered in the Russian Federation for use in patients with castration-resistant prostate cancer with bone metastases in the absence of visceral metastases, however, taking into account the tropism of Radium-223 chloride to bone tissue, a wide range of opportunities opens up for expanding the clinical use of Radium-223 chloride.
The main goal of the preclinical study is to confirm or refute the hypothesis that the clinically recommended dosage of radiopharmaceuticals based on radium chloride [223Ra] is sufficient to achieve an effective impact on tumor cell cultures that most often metastasize to bone tissue.
The method of choice in the design of a preclinical study is the quantitative and qualitative assessment of the radiobiological aspects of the effect of radium-223 alpha radiation on tumor cells in vitro.
The results of studying the pharmacokinetic and dosimetric characteristics of a domestic radiopharmaceutical drug based on Radium-223 chloride will make it possible to improve methods of treating oncological diseases and expand the areas of clinical use.
Key words: radium chloride 223Ra, radiopharmaceutical drug, preclinical study design, in vitro studies.